Pharma Is Priority As GSK Confirms Split With Consumer
Break-Up By July 2022
With CEO Emma Walmsley determined to keep investing in new technologies, GlaxoSmithKline has launched a two-year program to prepare for the separation of its pharma and consumer healthcare units into two companies.
You may also be interested in...
By combining its expertise in respiratory and vaccines, the UK drugs giant could have a potential blockbuster for chronic obstructive pulmonary disease, which is expected to become the third leading cause of death worldwide by the end of the decade.
GSK preparing to seize “a major opportunity to create a new leader in consumer h
GSK's CEO Emma Walmsley has effectively ruled out further big deals at its Consumer Healthcare unit before the business is separated from its parent through an IPO.